Yu-Jen Chen

Prof. Dr. Yu-Jen Chen

President, MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan
+3
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
Yu-Jen ChenYu-Jen Chen
Yu-Jen Chen
KHKai-Lung Hua
Kai-Lung Hua
CHChe-Hao Hsu
Che-Hao Hsu
WCWen-Huang Cheng
Wen-Huang Cheng
SHShintami Chusnul Hidayati
Shintami Chusnul Hidayati
Lung cancer has a poor prognosis when not diagnosed early and unresectable lesions are present. The management of small lung nodules noted on computed tomography scan is controversial due to uncertain tumor characteristics. A conventional computer-aided diagnosis (CAD) scheme requires several image processing and pattern recognition steps to accomplish a quantitative tumor differentiation result. In such an ad hoc image analysis pipeline, every step depends heavily on the performance of the previous step. Accordingly, tuning of classification performance in a conventional CAD scheme is very complicated and arduous. Deep learning techniques, on the other hand, have the intrinsic advantage of an automatic exploitation feature and tuning of performance in a seamless fashion. In this study, we attempted to simplify the image analysis pipeline of conventional CAD with deep learning techniques. Specifically, we introduced models of a deep belief network and a convolutional neural network in the context of nodule classification in computed tomography images. Two baseline methods with feature computing steps were implemented for comparison. The experimental results suggest that deep learning methods could achieve better discriminative results and hold promise in the CAD application domain.

Verified
Journal Article
Open access
PDF file
CCChing-Wei Chang
Ching-Wei Chang
HLHung-Chang Lee
Hung-Chang Lee
LLLilhi Li
Lilhi Li
JCJEN-SHIU CHIANG CHIAU
JEN-SHIU CHIANG CHIAU
TWTsang-En Wang
Tsang-En Wang
Yu-Jen ChenYu-Jen Chen
Yu-Jen Chen
FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), a 5-fluorouracil (5-FU)-based chemotherapy regimen, is one of most common therapeutic regimens for colorectal cancer. However, intestinal mucositis is a common adverse effect for which no effective preventive strategies exist. Moreover, the efficacy and the safety of fecal microbiota transplants (FMT) in cancer patients treated with anti-neoplastic agents are still scant. We investigated the effect of FMT on FOLFOX-induced mucosal injury. BALB/c mice implanted with syngeneic CT26 colorectal adenocarcinoma cells were orally administered FMT daily during and two days after five-day injection of FOLFOX regimen for seven days. Administration of FOLFOX significantly induced marked levels of diarrhea and intestinal injury. FMT reduced the severity of diarrhea and intestinal mucositis. Additionally, the number of goblet cells and zonula occludens-1 decreased, while apoptotic and NF-κB-positive cells increased following FOLFOX treatment. The expression of toll-like receptors (TLRs), MyD88, and serum IL-6 were upregulated following FOLFOX treatment. These responses were attenuated following FMT. The disrupted fecal gut microbiota composition was also restored by FMT after FOLFOX treatment. Importantly, FMT did not cause bacteremia and safely alleviated FOLFOX-induced intestinal mucositis in colorectal cancer-bearing mice. The putative mechanism may involve the gut microbiota TLR-MyD88-NF-κB signaling pathway in mice with implanted colorectal carcinoma cells.

15 May 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CCChing-Wei Chang
Ching-Wei Chang
CLChia-Yuan Liu
Chia-Yuan Liu
HLHung-Chang Lee
Hung-Chang Lee
YHYen-Hua Huang
Yen-Hua Huang
LLLi-Hui Li
Li-Hui Li
Yu-Jen ChenYu-Jen Chen
Yu-Jen Chen
Adjuvant 5-fluorouracil (5-FU)-based chemotherapy, including FOLFOX (5-FU, leucovorin, and oxaliplatin), is recommended for colorectal cancer. However, intestinal mucositis remains a common adverse effect for which no effective preventive strategies are available. To develop a convenient and novel way to alleviate mucositis, we investigated the effect of Lactobacillus casei variety rhamnosus (Lcr35) on FOLFOX-induced mucosal injury. BALB/c mice subcutaneously injected with syngeneic CT26 colorectal adenocarcinoma cells were orally administered Lcr35 daily before, during, and after 5-day injection of FOLFOX regimen, for 14 days. The following methods were used: diarrhea score for toxicity, ELISA for cytokine production, histopathology for intestinal injury, immunohistochemistry for apoptosis/proliferation and regulatory proteins, RT-PCR for cytokine mRNA expression, and DNA sequencing for fecal gut microbiota. FOLFOX administration to colorectal cancer-bearing mice significantly inhibited tumor growth and the accompanying marked diarrhea and intestinal injury histologically characterized by the shortening of villi and destruction of intestinal crypts. Preventive administration of Lcr35 dose-dependently reduced the severity of diarrhea and intestinal mucositis without affecting the anti-tumor effect of FOLFOX. The numbers of apoptotic, NF-κB-, and BAX-activated cells increased after FOLFOX, and these responses were mitigated by Lcr35. TNF-α and IL-6 upregulation by FOLFOX treatment was attenuated by Lcr35. The fecal gut microbiota composition of Firmicutes and Bacteroidetes disturbed by FOLFOX was significantly reversed by Lcr35 toward a preferential profile. In conclusion, the oral probiotic Lcr35 prevented FOLFOX-induced intestinal mucositis in colorectal cancer-bearing mice. The putative mechanism might involve modulation of gut microbiota and proinflammatory responses with suppression of intrinsic apoptosis in intestinal injury.

28 February 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
ICI Che Chung
I Che Chung
COChun-Nan OuYang
Chun-Nan OuYang
SYSheng-Ning Yuan
Sheng-Ning Yuan
TCTzong-Shi Chiueh
Tzong-Shi Chiueh
KHKuo-Yang Huang
Kuo-Yang Huang
LCLih-Chyang Chen
Lih-Chyang Chen
Colorectal cancer (CRC) is one of the most common malignancies worldwide. Inflammation contributes to cancer development and inflammatory bowel disease is an important risk factor for CRC. The aim of this study is to assess whether a widely used probiotic Enterococcus faecalis can modulate the NLRP3 inflammasome and protect against colitis and colitis-associated CRC. We studied the effect of heat-killed cells of E. faecalis on NLRP3 inflammasome activation in THP-1-derived macrophages. Pretreatment of E. faecalis or NLRP3 siRNA can inhibit NLRP3 inflammasome activation in macrophages in response to fecal content or commensal microbes, P. mirabilis or E. coli, according to the reduction of caspase-1 activation and IL-1β maturation. Mechanistically, E. faecalis attenuates the phagocytosis that is required for the full activation of the NLRP3 inflammasome. In in vivo mouse experiments, E. faecalis can ameliorate the severity of intestinal inflammation and thereby protect mice from dextran sodium sulfate (DSS)-induced colitis and the formation of CRC in wild type mice. On the other hand, E. faecalis cannot prevent DSS-induced colitis in NLRP3 knockout mice. Our findings indicate that application of the inactivated probiotic, E. faecalis, may be a useful and safe strategy for attenuation of NLRP3-mediated colitis and inflammation-associated colon carcinogenesis.

4 June 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
WHWen-Chien Huang
Wen-Chien Huang
MCMei-Lin Chan
Mei-Lin Chan
MCMing-Jen Chen
Ming-Jen Chen
Tung-Hu TsaiTung-Hu Tsai
Tung-Hu Tsai
Yu-Jen ChenYu-Jen Chen
Yu-Jen Chen
Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene

1 February 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
JLJie Lee
Jie Lee
JLJhen-Bin Lin
Jhen-Bin Lin
CCChih-Long Chang
Chih-Long Chang
FSFang-Ju Sun
Fang-Ju Sun
MWMeng-Hao Wu
Meng-Hao Wu
Yu-Jen ChenYu-Jen Chen
Yu-Jen Chen